Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
IZ

NASDAQ · IZTC

Invizyne Technologies Inc. Common Stock

Healthcare · Biotechnology

$16.50

Up+$1.00 (+6.45%)

Updated Aug 16, 2026, 9:24 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
157.23M
P/E ratio
-13.18
Dividend yield
0.00%
52-week range
— – —
Volume
12.04K
Avg. volume
36.9K

Price performance

IZTC price history

1M range · 0 trading sessions · Daily adjusted prices

IZTC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IZTC news

The latest Smart Investors Daily articles mentioning IZTC.

Stock researchCompany · Overview

IZTC research

Overview

Company profile and research snapshot.

Company profile

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Oct 26, 2025

Protalix BioTherapeutics (NYSE:PLX) vs. Invizyne Technologies (NASDAQ:IZTC) Critical Survey

Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and Invizyne Technologies (NASDAQ: IZTC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership. Analyst Recommendations This is a breakdown of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By